Enterovirus-71 (EV-71), a small member of the picornaviridae virus family, is a major causative agent of “hand foot and mouth”
HFMD disease in South East Asia. In some countries EV-71 related HFMD outbreaks appear to be increasing in magnitude and
frequency and are responsible for significant childhood mortality (905 deaths in China 2010) (est CFR 0.03%). Like Japanese
encephalitis (JEV), an inactivated EV-71 vaccine has high likelihood of region specific national adoption in the SE Asia. Four such
vaccines appear to be in late stage clinical trials in China with the first launch expected 2014.
This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of EV-71 vaccines to 2030 in the SE Asia region. The product examines different scenarios of sucessive country based vaccine deployment in the <1
yrs and 1-5 yrs age groups. Detailed coverage of latest EV-71 epidemiology (outbreaks) is included, also a focus on development
history/approaches to date and coverage of latest cost effectiveness issues. Expected revenues per competitor (public) sector are
included for the late stage Phase III programs operated by Sinovac and China National Biotech Group (Beijing Vigoo Biological Co
This product is an ideal starting point for any manufacturer wishing to assess this emerging market in the SE Asia region.
THIS PRODUCT IS A EXECUTIVE PRESENTATION + 2 MODELS